# Walk101 Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/walk101-co

- Industry: Software
- Headquarters: Incheon, South Korea
- Website: www.walk101.co.kr/
- Latest round: Seed (Dec 5, 2025)
- Investors on record: 1

## About

Based in Incheon, South Korea, Walk101 Co., Ltd. specializes in musculoskeletal diagnostic software and data analysis, providing effective health solutions aimed at enhancing mobility and promoting healthy aging for individuals and healthcare providers.Walk101 Co., Ltd. was founded in 2023 in Incheon, South Korea. The company develops innovative diagnostic software focused on musculoskeletal health. Founded by Dong-sik Chae, who serves as CEO, Walk101 has already completed two deals, with the most recent deal occurring on December 5, 2025, through an investment target from Korea Tech Incubator for Startup.Walk101 specializes in the development of innovative musculoskeletal diagnostic software and the analysis of multimodal data to provide effective solutions for hospitals, manufacturers, and individuals aimed at promoting healthy walking well into old age. The core offerings focus on advanced diagnostic tools that facilitate the assessment of musculoskeletal health, enabling healthcare providers to deliver targeted treatments and interventions. Their solutions cater to a diverse client base, including healthcare facilities, medical device manufacturers, and end-users seeking to improve their mobility and overall health. The company’s products are primarily marketed in the Asian and North American regions, where there is a growing demand for health technology solutions that address age-related mobility issues.Walk101's revenue model is structured around direct sales and partnerships with healthcare institutions and manufacturers that integrate their diagnostic software into existing systems. Business transactions typically involve licensing agreements or subscriptions, allowing clients ongoing access to the software and its updates. The company maintains relationships with various stakeholders, including hospitals and rehabilitation centers, facilitating the adoption of their products through tailored support and training. Pricing plans for these services are strategically designed to reflect the value provided to healthcare providers and their patients, ensuring competitive positioning within the health tech market. The flagship products associated with Walk101 reflect their commitment to enhancing musculoskeletal diagnostics and promoting health longevity.Walk101 Co., Ltd. aims to leverage its recent funding raised in December 2025 to accelerate the development of its core technology, including the Large Musculoskeletal Model, while reinforcing self-learning capabilities based on clinical data and refining its global SaaS architecture. The company plans to introduce new products to the market and expand into new geographic regions, notably targeting growth in the Asian and North American markets. The funding will support these initiatives, allowing Walk101 to enhance its technological offerings and better serve its clients.

## Funding rounds

- Seed, Dec 5, 2025 — Merry Year Social Company

## Investors

- Merry Year Social Company (https://capitalatlas.ai/funds/merry-year-social-company) — Seed